uniQure (NASDAQ:QURE) Shares Gap Up - What's Next?

uniQure (NASDAQ:QURE - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $14.77, but opened at $15.97. uniQure shares last traded at $15.36, with a volume of 404,554 shares traded.

Wall Street Analyst Weigh In

QURE has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. StockNews.com raised uniQure to a "sell" rating in a report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. Finally, Chardan Capital reaffirmed a "buy" rating and set a $38.00 price target on shares of uniQure in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, uniQure has a consensus rating of "Moderate Buy" and an average target price of $38.80.

uniQure Stock Performance

The stock has a market capitalization of $589.39 million, a price-to-earnings ratio of -2.17 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a 50-day moving average of $12.16 and a 200-day moving average of $11.97.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 in the last ninety days. Insiders own 4.74% of the company's stock.

Institutional Investors Weigh In On uniQure

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after buying an additional 969 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock worth $438,000 after acquiring an additional 1,371 shares in the last quarter. Wells Fargo & Company MN grew its position in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after acquiring an additional 1,503 shares in the last quarter. Northern Trust Corp grew its holdings in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock worth $1,253,000 after buying an additional 3,996 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.